Skip to content
You are now leaving to visit

Akcea and Ionis receive positive EU CHMP opinion for WAYLIVRATM (volanesorsen)

First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,